Evidence map›Paper›PMID 37513328›Full record

ArticleMolecules (Basel, Switzerland)2023

Four Meroterpenoids with Novel Aminoglycoside Moiety from the Basidiomycete

Zhonghao Sun, Yongben Ma, Jiawen Zhang, Guoxu Ma, Haifeng Wu, Leiling Shi, Zhaocui Sun, Xudong Xu

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhonghao SunInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China.
Yongben MaSchool of Pharmaceutical Sciences, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.
Jiawen ZhangInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China.
Guoxu MaInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China.
Haifeng WuInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China.ORCID 0000-0002-1984-9114
Leiling ShiXinjiang Institute of Chinese and Ethnic Medicine, Urumqi 830002, China.
Zhaocui SunInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China.
Xudong XuInstitute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China.

Funding

Fundamental Research Funds for the Central Universities 3332033050National Natural Science Foundation of China 82073718, 82160668the CAMS Innovation Fund for Medical Sciences 2022-I2M-1-017
6 · The paper itself

Abstract

Four new meroterpenoids, Clavilactone M-P, possessing novel aminoglycoside moiety (

Indexed as

Antineoplastic AgentsBasidiomycotaAgaricalesAminoglycosidesAnti-Bacterial AgentsCell Line, TumorHumansMolecular StructureAminoglycosidesAnti-Bacterial AgentsAntineoplastic AgentsclavilactoneClitocybe clavipescytotoxicitymeroterpenoid

Identifiers

PMID37513328
PMCPMC10384625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.